Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.
News|Videos|May 21, 2024
ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design
Author(s)Brian M. Slomovitz, MD
Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.
Advertisement
Advertisement
Related to this article
Selinexor maintenance failed to significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in the phase 3 XPORT-EC-042 trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
The OncFive: Top Oncology Articles for the Week of 8/2
3
Exploring the Rationale for 5-Alpha Reductase Inhibitors in Prostate Cancer Prevention and Active Surveillance
4
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
5